Potential of circulating pro‐angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention

Abstract

Background:This study aimed to investigate the correlation of pro-angiogenic micro-RNA (miRNA) expressions with rapid angiographic stenotic progression (RASP) and restenosis risks in coronary artery disease (CAD) patients underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Methods:A total of 286 CAD patients underwent PCI with DES were consecutively recruited in this study. Plasma samples were collected before PCI operation, and 14 pro-angiogenic miRNAs were measured by real-time quantitative reverse transcription-polymerase chain reaction. Rapid angiographic stenotic progression at nontarget lesions and restenosis at stented lesions were evaluated by quantitative coronary angiography at 12 months after PCI operation. Results:The occurrence rates of RASP and restenosis were 39.5% and 22.4%, respectively. , and miR-296 were decreased in RASP patients than non-RASP patients, among which let-7f, miR-19a, miR-126, miR-210, and miR-296 independently correlated with lower RASP occurrence by multivariate analysis, followed by receiver-operating characteristic (ROC) curve exhibited that these five miRNAs showed great value in predicting RASP risk with area under curve (AUC) 0.879 (95% CI: 0.841-0.917). Besides, let-7f, miR-19a, miR-92a, miR-126, miR-130a, and miR-210 were reduced in restenosis patients than non-restenosis patients, among them miR-19a, miR-126, miR-210, and miR-378 independently correlated with lower restenosis occurrence by multivariate analysis, followed by ROC curve disclosed that these four miRNAs had good value in predicting restenosis risk with AUC 0.776 (95% CI: 0.722-0.831). Conclusions:Circulating let-7f, miR-19a, miR-126, miR-210, and miR-296 independently correlate with reduced RASP risk, while miR-19a, miR-126, miR-210, and

The Current State of MicroRNAs as Restenosis Biomarkers

“…Even though the results shown are encouraging, an important weakness of the study lies in the lack of additional validation in an independent cohort, restricting the extent of the results. Very recently, Dai et al selected 14 angiogenesis-related candidate miRNAs (Dai et al, 2019) and reported 4 as independently associated with decreased restenosis risk . ROC curves showed that this subgroup of miRNAs had better predictive values for restenosis occurrence in Chinese population than each on its own (AUC: 0.776; 95% CI: 0.722-0.831).…”

“…A persistent but reasonable shortcoming regarding miRNA research as biomarkers for restenosis is represented by the candidate approach, i.e., handpicking specific RNA molecules exclusively based on previous reports. Although most of these investigations have solid grounds since they are based on the choice of miRNAs previously associated with restenosis-related mechanisms, the success rates contrast with what one might expect, since they are not even close to 100%, as the case of different studies mentioned above (Stojkovic et al, 2018;Dai et al, 2019). The candidate approach is predominantly used because is significantly less expensive than other wide-ranging strategies, such as microarray or NGS, but the loss of information can be excessive.…”

MicroRNAs: New Biomarkers for the progression of Coronary Artery Diseases

“…A remarkably decreased level of serum miRNA-143 has been reported in ISR group compared with the control one, showing its potential in serving as an effective biomarker [45] . It has been suggested that the major cause of ISR is the migration and proliferation of VSMCs, which could induce the generation of neointima and further lead to restenosis [6,45] . A study based on a mouse model of ISR demonstrated that the lack of miR-21 could weaken neointima formation and macrophage activation, thus resulting in a less inflammatory phenotype [34] .…”

“…At present, ISR [4] [4] , MI, stent thrombosis and several complications after PCI remain to be challenging problems [5] , which have gradually attracted widespread attention. As a result, identification of timely and reliable diagnostic-and prognostic-biomarkers for CADs is of great value for the precaution and medical treatment of the disease [6], [7] . Recently, increasing evidence has suggested that multiple microRNAs (miRNAs) are dysregulated in CADs.…”

Predictive value of miRNA-21 on coronary restenosis after percutaneous coronary intervention in patients with coronary heart disease

“…Previous studies have confirmed the abnormal expression of miRNA-21 in patients with coronary restenosis after PCI, indicating that miRNA-21 has potential diagnostic value. [ 20 , 21 ] Current evidence suggests that miRNA-21 may be a new biomarker and potential therapeutic target for the prediction of coronary restenosis in patients with CHD after PCI, but there are different reports. [ 21 – 24 ] Therefore, this study adopts the method of meta-analysis for quantitative and comprehensive statistics to comprehensively and objectively evaluate the predictive value of miRNA-21 in patients with CHD after PCI.…”